Mode
Text Size
Log in / Sign up
N/A N=61 Randomized Double-blind Treatment

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD)

Post Traumatic Stress Disorder

Enrolled (actual)
61
Serious AEs
3.3%
Results posted
Mar 2026
Primary outcome: Primary: Change (From Intake to Post-therapy) in Resting-state Functional Connectivity Between Posterior Cingulate Cortex (PCC) and Dorsolateral Prefrontal Cortex (dlPFC) — 0.0417; -0.0262 rsFC Beta change score intake to post — p=0.002

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Mindfulness-Based Cognitive Therapy (Behavioral); Muscle Relaxation Therapy (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ohio State University
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change (From Intake to Post-therapy) in Resting-state Functional Connectivity Between Posterior Cingulate Cortex (PCC) and Dorsolateral Prefrontal Cortex (dlPFC)
0.0417; -0.0262 0.002 sig
SECONDARY
Change (From Intake to Post-therapy) in Resting-state Functional Connectivity (rsFC) Between Posterior Cingulate Cortex (PCC) and Insula Cortex (Insula)
-0.0067; -0.0240; -0.0031; -0.0223 0.190

Summary

This study will examine the effects of psychotherapy as treatment for PTSD, and specifically how brain activity and brain connectivity is affected by Mindfulness Based Cognitive Therapy (MBCT) and an active mind-body comparison comparison therapy.

Eligibility Criteria

Inclusion Criteria

  • Meets current Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for PTSD (with or without Major Depressive Disorder) or subsyndromal PTSD (has qualifying trauma, has intrusive and avoidant symptoms, and at least one negativity and one arousal symptom, and significant impairment); type of trauma shall be interpersonal violence, combat, and/or sexual assault, etc.

Exclusion Criteria

  • Dissociative PTSD
  • Delayed-onset PTSD
  • Magnetic Resonance Imaging (MRI) contraindications (e.g. metal in body, inability to be in the scanner - claustrophobia, severe back pain, etc.)
  • Serious medical or neurologic conditions (e.g. stroke, seizures)
  • Suicide risk
  • Psychosis
  • Life history of schizophrenia
  • Life history of bipolar disorder
  • Current substance dependence
  • Other factors that preclude safe and meaningful participation in the study, at discretion of the PI and study team
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03874793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search